Zimmer Biomet (ZBH) Earns “Buy” Rating from BMO Capital Markets

BMO Capital Markets restated their buy rating on shares of Zimmer Biomet (NYSE:ZBH) in a report published on Tuesday. The brokerage currently has a $142.00 price objective on the medical equipment provider’s stock.

Other equities research analysts have also recently issued reports about the company. Deutsche Bank upgraded Zimmer Biomet from a hold rating to a buy rating and set a $128.00 target price for the company in a research note on Tuesday, November 14th. Edward Jones upgraded Zimmer Biomet from a hold rating to a buy rating in a research note on Thursday, November 9th. Jefferies Group restated a buy rating and set a $136.00 target price on shares of Zimmer Biomet in a research note on Friday, November 3rd. Gabelli initiated coverage on Zimmer Biomet in a research note on Thursday, August 24th. They set a buy rating and a $142.00 target price for the company. Finally, Oppenheimer set a $137.00 target price on Zimmer Biomet and gave the stock a buy rating in a research note on Monday, August 14th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of Hold and an average target price of $134.05.

Shares of Zimmer Biomet (NYSE:ZBH) opened at $112.82 on Tuesday. The stock has a market capitalization of $22,984.75, a P/E ratio of 14.07, a P/E/G ratio of 1.76 and a beta of 1.15. Zimmer Biomet has a 12-month low of $100.81 and a 12-month high of $133.49. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The company’s quarterly revenue was down .8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.79 EPS. analysts forecast that Zimmer Biomet will post 8.03 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bessemer Group Inc. grew its holdings in Zimmer Biomet by 21.1% during the 2nd quarter. Bessemer Group Inc. now owns 4,297 shares of the medical equipment provider’s stock worth $552,000 after acquiring an additional 750 shares during the period. Sei Investments Co. grew its holdings in Zimmer Biomet by 11.6% during the 2nd quarter. Sei Investments Co. now owns 53,993 shares of the medical equipment provider’s stock worth $6,932,000 after acquiring an additional 5,625 shares during the period. IFP Advisors Inc grew its holdings in Zimmer Biomet by 22.4% during the 2nd quarter. IFP Advisors Inc now owns 2,077 shares of the medical equipment provider’s stock worth $267,000 after acquiring an additional 380 shares during the period. Global X Management Co. LLC grew its holdings in Zimmer Biomet by 41.6% during the 2nd quarter. Global X Management Co. LLC now owns 6,315 shares of the medical equipment provider’s stock worth $811,000 after acquiring an additional 1,854 shares during the period. Finally, Trexquant Investment LP acquired a new stake in Zimmer Biomet during the 2nd quarter worth about $231,000. Institutional investors and hedge funds own 86.24% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Zimmer Biomet (ZBH) Earns “Buy” Rating from BMO Capital Markets” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.com-unik.info/2017/12/15/zimmer-biomet-zbh-earns-buy-rating-from-bmo-capital-markets.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

What are top analysts saying about Zimmer Biomet? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit